Gastrectomy, Gastric Bypass, Obesity
Conditions
Keywords
Cholecalciferol
Brief summary
Set the pattern of vitamin D supplementation in obese patients undergoing bariatric surgery in deficit of vitamin D. Patients receive a single oral dose of vitamin D, during the 28 days will be done a kinetic curve. Then and over the next 3 months, levels are normalized. Once normalized, will be administered another single oral dose to a second pharmacokinetic evaluation.
Detailed description
The study is conducted in obese patients undergoing bariatric surgery (for bypass or sleeve gastrectomy) in deficit of vitamin D. Will include a total of 44 patients, 22 from each type of surgery. Patients receive a single oral dose of vitamin D of 50,000 IU. During the 28 days after administration of vitamin D will be done a kinetic curve determining plasma levels of vitamin D on 15 occasions. Then and over the next 3 months, levels are normalized by providing a daily oral dose for each patient. Once levels are normalized, will be administered another single oral dose of 50,000 IU vitamin D and proceed to a second pharmacokinetic evaluation determining plasma levels 15 times. Patient follow up is approximately 36 weeks. Patients go to the screening visit, baseline visit and visits on days 1, 2, 3, 14 and 28 days after each pharmacokinetic evaluation.
Interventions
DRUGCholecalciferol
One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
Sponsors
Hospital Clinic of Barcelona
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 or more years old * with bariatric surgery in the last 18 months (+/- 6 months) * BMI: 25-33 kg/m2 * vitamin D3 (OK)\<20ng/mL. * Clinically stable, in the opinion of the investigator, at the time of inclusion * Signed consent form
Exclusion criteria
* pregnancy, lactation or intention during the study period. * menopause * GOP, GPT\>2 UNL * glomerular filtration rate \<60ml/min * previous renal lithiasis * any digestive disease to suggest malabsorption, granulomatous diseases, diabetic gastroenteropathy and taking medication likely to interfere with the absorption of vitamin D and bone metabolism such as corticosteroids and anticonvulsants * taking medication that interferes with calcium metabolism. * cholecalciferol hypersensitivity. * other bariatric surgery (different of by-pass or tubular gastrectomy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of pharmacokinetic parameters | 36 weeks | Comparison of the pharmacokinetic parameters of vitamin D according to a non compartimental approach (AUC0-t, AUC0-∞, Cmax and t1/2) between a state of vitamin D and after normalization of the same. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with secondary hyperparathyroidism in both surgeries. | 36 weeks | — |
| Change from baseline levels of urinary excretion of calcium in both surgeries | 36 weeks | — |
| Change from baseline levels of urinary excretion creatinine in both surgeries | 36 weeks | — |
| Change from baseline in both biochemistry surgery | 36 weeks | Changes in total protein, albumin, phosphorus, magnesium and calcium will be analyzed. |
| Comparison of the pharmacokinetic parameters between the two types of surgery | 36 weeks | Comparison of the pharmacokinetic parameters of vitamin D according to a non-compartmental approach (AUC0-t, AUC0-∞, Cmax and t1 / 2) between the two types of surgery (bypass and sleeve gastrectomy) |
| Change from baseline body fat distribution by DEXA | 36 weeks | — |
| Changes adherence in both surgeries | 36 weeks | — |
| Incidence of adverse and clinical laboratory events for each of the surgeries | 36 weeks | — |
| Proportion of patients with serious adverse events related to medication | 36 weeks | — |
| Change from baseline alkaline phosphatase levels in both surgeries | 36 weeks | — |
Countries
Spain
Contacts
Primary ContactVioleta Moize, MD
Outcome results
None listed